Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04347954 · ClinicalTrials.gov registry record · Phase 1
PVP-I Nasal Sprays and SARS-CoV-2 Nasopharyngeal Titers (for COVID-19)
A Phase 1 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 1
- Development phase
- 47
- Enrollment target
NCT04347954: Completed Phase 1 study, sponsored by Stanford University.
NCT04347954 is a Phase 1 study that has completed, run by Stanford University. The registered enrollment target is 47 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04347954, a Phase 1 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 47 participants
- Enrollment target
Study Summary
The study aims to determine the safety and efficacy of povidone-iodine (PVP-I) containing nasal sprays as compared to isotonic saline nasal sprays in COVID-19 positive patients. The primary outcome measure is SARS-CoV-2 viral titers in the nasal cavity and nasopharynx. In vitro studies have shown PVP-I to be highly virucidal against the viruses which cause SARS and MERS. Additionally, clinical studies have shown PVP-I saline sprays to be well tolerated in human subjects. PVP-I oral rinses and sprays have been trialed as methods to reduce the incidence and symptoms of viruses which cause the "common cold."
Interventions
- DRUG Povidone-Iodine 2%
- DRUG Povidone-Iodine 0.5%
- DRUG Isotonic saline 0.9%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2020-08-15 |
| Est. Completion | 2020-12-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04347954
The ClinicalTrials.gov registry entry for NCT04347954 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Povidone-Iodine 2% is the first listed.
NCT04347954 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04347954 about?
NCT04347954 is a clinical study titled "PVP-I Nasal Sprays and SARS-CoV-2 Nasopharyngeal Titers (for COVID-19)". The study aims to determine the safety and efficacy of povidone-iodine (PVP-I) containing nasal sprays as compared to isotonic saline nasal sprays in COVID-19 positive patients. The primary outcome measure is SARS-CoV-2 viral titers in the nasal cavity and nasopharynx. In vitro studies have shown PV...
What is the current status of trial NCT04347954?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 2020-08-15. Estimated completion is 2020-12-13.
What interventions are being tested in trial NCT04347954?
The interventions under investigation include: Povidone-Iodine 2% (DRUG), Povidone-Iodine 0.5% (DRUG), Isotonic saline 0.9% (DRUG).
Who is sponsoring clinical trial NCT04347954?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.